AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,188 | +157.3% | 339,846 | +137.5% | 0.01% | +175.0% |
| Q2 2023 | $6,680 | +126.1% | 143,078 | +85.3% | 0.00% | +300.0% |
| Q1 2023 | $2,954 | -47.9% | 77,224 | -25.4% | 0.00% | -66.7% |
| Q4 2022 | $5,674 | -85.8% | 103,552 | +8616.5% | 0.00% | – |
| Q3 2022 | $40,000 | -64.9% | 1,188 | -90.2% | 0.00% | – |
| Q2 2022 | $114,000 | +6.5% | 12,078 | +58.7% | 0.00% | – |
| Q1 2022 | $107,000 | -92.9% | 7,610 | -89.3% | 0.00% | – |
| Q4 2021 | $1,498,000 | +375.6% | 70,860 | +403.7% | 0.00% | – |
| Q3 2021 | $315,000 | +131.6% | 14,068 | +156.9% | 0.00% | – |
| Q2 2021 | $136,000 | -63.1% | 5,476 | -57.1% | 0.00% | – |
| Q1 2021 | $369,000 | +141.2% | 12,757 | +114.8% | 0.00% | – |
| Q4 2020 | $153,000 | -39.3% | 5,938 | -27.3% | 0.00% | – |
| Q3 2020 | $252,000 | -41.9% | 8,169 | -53.0% | 0.00% | – |
| Q2 2020 | $434,000 | +635.6% | 17,399 | +525.4% | 0.00% | – |
| Q1 2020 | $59,000 | -47.3% | 2,782 | -44.6% | 0.00% | – |
| Q4 2019 | $112,000 | +83.6% | 5,018 | +88.9% | 0.00% | – |
| Q3 2019 | $61,000 | – | 2,657 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
| Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
| Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
| Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
| Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
| COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
| Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
| Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
| Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |